URINARY BLADDER NEOPLASMS

This is an early safety study for a new device called TAR-210, which is placed in the bladder to slowly release a cancer drug. It is being tested in 5 Japanese patients with a specific type of recurring bladder cancer that has certain genetic changes. The main goal is to see how …

This study is testing two experimental drug approaches for people with muscle-invasive bladder cancer who are scheduled to have their bladder removed. One approach uses a drug-releasing device placed in the bladder plus an IV immunotherapy drug. The other uses just the IV drug al…

This study is testing an experimental drug called enfortumab vedotin, both by itself and combined with other cancer therapies, for people with advanced bladder and urinary tract cancers. It aims to find safe doses and see if these treatments can shrink tumors. The study includes …

This study is testing whether adding a pill called olaparib to an immunotherapy drug (durvalumab) works better than the immunotherapy alone for patients with advanced bladder cancer that has spread and cannot be removed by surgery. The patients in this trial are not eligible for …

This study is testing new treatments for people with high-risk, early-stage bladder cancer that has not responded to standard BCG therapy and who cannot or choose not to have their bladder removed. It will compare a drug-releasing implant (TAR-200), an immunotherapy (cetrelimab),…

This study is for people with muscle-invasive bladder cancer who cannot or choose not to have their bladder surgically removed. It compares a new treatment approach—a drug-releasing device placed in the bladder plus an immunotherapy infusion—against the current standard treatment…

This large, late-stage study is testing whether adding immunotherapy drugs (nivolumab with or without BMS-986205) to standard chemotherapy before bladder removal surgery, and continuing them afterward, works better than chemotherapy alone. It involves 855 adults with muscle-invas…